On April 11, 2018 Percans Oncology reported that it has developed i-CR, a personalized drug susceptibility testing platform for the precise treatment of colon cancer, to provide clinicians and patients with the most valuable medical plan for reference (Press release, Cothera Bioscience, APR 11, 2018, View Source [SID1234618854]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Features of i-CR in vitro drug susceptibility testing platform

i-CR drug susceptibility testing technology focuses on the functionality of tumor cells. It investigates the response of tumor cells under the action of drugs instead of exploring the relationship between drug susceptibility and changes in genes and proteins. The i-CR results are more practical and correspondence to clinical outcomes. This technology takes small samples of patients’ tumors, and performs rapid and high-throughput, drug susceptibility tests for drugs that have been marketed or entered clinical trials, thus providing a strong basis for clinicians to make optmized medical plans for each individual patient.

Target Patients

l Patients newly diagnosed as stage III or IV colorectal cancer;

l Patients who have failed the standard first-line treatment plan and hope to choose the best plan;

l Patients who have local or distant metastases and cannot benefit from genetic testing;

l Patients who are resistant to targeted drugs and need to find effective multiple targeted drugs and targeted combinations.